Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2019 16:35 ET | Source: Vital Therapies, Inc.

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019

SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to...
April 04, 2019 16:07 ET | Source: Vital Therapies, Inc.

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG

SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with...
March 27, 2019 06:00 ET | Source: Vital Therapies, Inc.

Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG

Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go...
March 25, 2019 05:00 ET | Source: Vital Therapies, Inc.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals

SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both...
March 04, 2019 16:10 ET | Source: Vital Therapies, Inc.

Vital Therapies Announces 2018 Financial Results

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute...
January 07, 2019 04:00 ET | Source: Vital Therapies, Inc.

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an...
November 07, 2018 18:20 ET | Source: Vital Therapies, Inc.

Vital Therapies Announces Third Quarter 2018 Financial Results

SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms...
October 11, 2018 09:27 ET | Source: Vital Therapies, Inc.

Vital Therapies Provides Strategic Update

SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver...
September 29, 2018 10:00 ET | Source: Vital Therapies, Inc.

Vital Therapies to Present at the 19th International Liver Support Meeting

SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver...
September 12, 2018 05:00 ET | Source: Vital Therapies, Inc.

Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival

SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...

Next Page keyboard_arrow_right